Literature DB >> 17726644

Glutamate uptake is reduced in prefrontal cortex in Huntington's disease.

Bjørnar Hassel1, Shoshi Tessler, Richard L M Faull, Piers C Emson.   

Abstract

Huntington's disease (HD) is caused by a CAG repeat expansion in the HD gene, but how this mutation causes neuronal dysfunction and degeneration is unclear. Inhibition of glutamate uptake, which could cause excessive stimulation of glutamate receptors, has been found in animals carrying very long CAG repeats in the HD gene. In seven HD patients with moderate CAG expansions (40-52), repeat expansion and HD grade at autopsy were strongly correlated (r=0.88, p=0.0002). Uptake of [(3)H]glutamate was reduced by 43% in prefrontal cortex, but the level of synaptic (synaptophysin, AMPA receptors) and astrocytic markers (GFAP, glutamate transporter EAAT1) were unchanged. Glutamate uptake correlated inversely with CAG repeat expansion (r= -0.82, p=0.015). The reducing agent dithiothreitol improved glutamate uptake in controls, but not in HD brains, suggesting irreversible oxidation of glutamate transporters in HD. We conclude that impairment of glutamate uptake may contribute to neuronal dysfunction and degeneration in HD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17726644     DOI: 10.1007/s11064-007-9463-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  36 in total

1.  Correlation between triplet repeat expansion and computed tomography measures of caudate nuclei atrophy in Huntington's disease.

Authors:  B Culjkovic; O Stojkovic; N Vojvodic; M Svetel; L Rakic; S Romac; V Kostic
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

2.  Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease.

Authors:  R L Albin; A B Young; J B Penney; B Handelin; R Balfour; K D Anderson; D S Markel; W W Tourtellotte; A Reiner
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.

Authors:  J C Liévens; B Woodman; A Mahal; O Spasic-Boscovic; D Samuel; L Kerkerian-Le Goff; G P Bates
Journal:  Neurobiol Dis       Date:  2001-10       Impact factor: 5.996

5.  Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate.

Authors:  J D Rothstein; M Dykes-Hoberg; C A Pardo; L A Bristol; L Jin; R W Kuncl; Y Kanai; M A Hediger; Y Wang; J P Schielke; D F Welty
Journal:  Neuron       Date:  1996-03       Impact factor: 17.173

Review 6.  Glutamate uptake.

Authors:  N C Danbolt
Journal:  Prog Neurobiol       Date:  2001-09       Impact factor: 11.685

7.  Trafficking of amino acids between neurons and glia in vivo. Effects of inhibition of glial metabolism by fluoroacetate.

Authors:  B Hassel; H Bachelard; P Jones; F Fonnum; U Sonnewald
Journal:  J Cereb Blood Flow Metab       Date:  1997-11       Impact factor: 6.200

8.  Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease.

Authors:  Miguel Díaz-Hernández; Jesús Torres-Peraza; Alejandro Salvatori-Abarca; María A Morán; Pilar Gómez-Ramos; Jordi Alberch; José J Lucas
Journal:  J Neurosci       Date:  2005-10-19       Impact factor: 6.167

9.  Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation.

Authors:  P F Behrens; P Franz; B Woodman; K S Lindenberg; G B Landwehrmeyer
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

10.  Glutamate transport, glutamine synthetase and phosphate-activated glutaminase in rat CNS white matter. A quantitative study.

Authors:  Bjørnar Hassel; Karen Astrid Boldingh; Cecilie Narvesen; Evy Grini Iversen; Knut Kristian Skrede
Journal:  J Neurochem       Date:  2003-10       Impact factor: 5.372

View more
  51 in total

Review 1.  Polyglutamine toxicity in non-neuronal cells.

Authors:  Jennifer W Bradford; Shihua Li; Xiao-Jiang Li
Journal:  Cell Res       Date:  2010-03-16       Impact factor: 25.617

Review 2.  The influence of cannabinoids on generic traits of neurodegeneration.

Authors:  S G Fagan; V A Campbell
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

3.  Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders.

Authors:  Alexei Verkhratsky; Vladimir Parpura
Journal:  Neurobiol Dis       Date:  2015-04-03       Impact factor: 5.996

4.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

5.  Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease.

Authors:  Junmei Wan; Jeffrey N Savas; Amy F Roth; Shaun S Sanders; Roshni R Singaraja; Michael R Hayden; John R Yates; Nicholas G Davis
Journal:  Chem Biol       Date:  2013-11-07

6.  Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.

Authors:  Ana María Estrada-Sánchez; Courtney L Burroughs; Stephen Cavaliere; Scott J Barton; Shirley Chen; X William Yang; George V Rebec
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

7.  Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms.

Authors:  Jennifer Bradford; Ji-Yeon Shin; Meredith Roberts; Chuan-En Wang; Xiao-Jiang Li; Shihua Li
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

8.  Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.

Authors:  Geraldine T Petr; Laurel A Schultheis; Kayla C Hussey; Yan Sun; Janet M Dubinsky; Chiye Aoki; Paul A Rosenberg
Journal:  Eur J Neurosci       Date:  2013-04-16       Impact factor: 3.386

9.  Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease.

Authors:  Youssef Sari; Anne L Prieto; Scott J Barton; Benjamin R Miller; George V Rebec
Journal:  J Biomed Sci       Date:  2010-07-27       Impact factor: 8.410

10.  Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.

Authors:  B R Miller; J L Dorner; M Shou; Y Sari; S J Barton; D R Sengelaub; R T Kennedy; G V Rebec
Journal:  Neuroscience       Date:  2008-02-15       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.